
## E Dianne Pulte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8728681/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. Journal of Clinical Oncology, 2022, 40, 847-854.	1.6	13
2	Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time. Leukemia and Lymphoma, 2022, 63, 1964-1969.	1.3	2
3	FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> Mutation. Clinical Cancer Research, 2021, 27, 3515-3521.	7.0	42
4	Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer Journal, 2020, 10, 56.	6.2	67
5	Changes in populationâ€level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. Cancer, 2019, 125, 2656-2665.	4.1	15
6	U.S. Food and Drug Administration Benefitâ€Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission. Oncologist, 2019, 24, e188-e195.	3.7	1
7	Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century. International Journal of Cancer, 2018, 143, 324-332.	5.1	5
8	Disparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis. Diseases of the Colon and Rectum, 2018, 61, 538-546.	1.3	33
9	Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Advances, 2018, 2, 116-119.	5.2	19
10	FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. Oncologist, 2018, 23, 1366-1371.	3.7	40
11	Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003–2014: a large international populationâ€based study. International Journal of Cancer, 2018, 143, 3227-3239.	5.1	25
12	Population-Level Differences in Rectal Cancer Survival in Uninsured Patients Are Partially Explained by Differences in Treatment. Oncologist, 2017, 22, 351-358.	3.7	7
13	Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 st century. Haematologica, 2017, 102, e229-e232.	3.5	8
14	Outcome disparities by insurance type for patients with acute myeloblastic leukemia. Leukemia Research, 2017, 56, 75-81.	0.8	9
15	Social disparities in survival after diagnosis with colorectal cancer: Contribution of race and insurance status. Cancer Epidemiology, 2017, 48, 41-47.	1.9	25
16	Survival for patients with rare haematologic malignancies: Changes in the early 21st century. European Journal of Cancer, 2017, 84, 81-87.	2.8	8
17	Population-Level Survival for Patients With Chronic Myeloid Leukemia: Higher Survival in Sweden Than Internationally. Journal of Clinical Oncology, 2017, 35, 695-696.	1.6	2
18	Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults. International Journal of Cancer, 2016, 139, 1289-1296.	5.1	17

E DIANNE PULTE

#	Article	IF	CITATIONS
19	Determining the role of smoking in myeloproliferative neoplasms: is it a matter of picking the right control group?. European Journal of Haematology, 2016, 97, 3-4.	2.2	1
20	Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer, 2016, 122, 2031-2040.	4.1	46
21	Case series of octogenarians with sickle cell disease. Blood, 2016, 128, 2367-2369.	1.4	16
22	Comparison of Emergency Department Wait Times in Adults with Sickle Cell Disease Versus Other Painful Etiologies. Hemoglobin, 2016, 40, 330-334.	0.8	8
23	Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. Journal of Hematology and Oncology, 2016, 9, 28.	17.0	40
24	Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. British Journal of Haematology, 2015, 171, 189-196.	2.5	80
25	In Reply. Oncologist, 2015, 20, 1224-1224.	3.7	0
26	Survival of patients with gastric lymphoma in <scp>G</scp> ermany and in the <scp>U</scp> nited <scp>S</scp> tates. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1485-1491.	2.8	13
27	Survival Disparities by Insurance Type for Patients Aged 15–64 Years With Non-Hodgkin Lymphoma. Oncologist, 2015, 20, 554-561.	3.7	21
28	Survival for patients with chronic leukemias in the <scp>US</scp> and Britain: Ageâ€related disparities and changes in the early 21st century. European Journal of Haematology, 2015, 94, 540-545.	2.2	29
29	Survival disparities by age and country of diagnosis for patients with acute leukemia. Leukemia and Lymphoma, 2015, 56, 2787-2792.	1.3	10
30	Influence of insurance type on survival in patients with acute myeloblastic leukemia Journal of Clinical Oncology, 2015, 33, e17612-e17612.	1.6	1
31	Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years. Blood, 2015, 126, 4599-4599.	1.4	0
32	Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States. PLoS ONE, 2014, 9, e85554.	2.5	86
33	Erythropoietin Levels in Patients with Sickle Cell Disease Do Not Correlate with Known Inducers of Erythropoietin. Hemoglobin, 2014, 38, 385-389.	0.8	6
34	Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leukemia and Lymphoma, 2014, 55, 1083-1089.	1.3	82
35	Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. British Journal of Haematology, 2014, 164, 851-857.	2.5	17
36	Age disparities in survival from lymphoma and myeloma: a comparison between <scp>US</scp> and <scp>E</scp> ngland. British Journal of Haematology, 2014, 165, 824-831.	2.5	18

E DIANNE PULTE

#	Article	IF	CITATIONS
37	Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. Journal of Hematology and Oncology, 2013, 6, 70.	17.0	20
38	Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. Leukemia and Lymphoma, 2013, 54, 979-985.	1.3	20
39	Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica, 2013, 98, 222-229.	3.5	86
40	An International Comparison Of Survival Disparities In Patients With Lymphoma and Myeloma. Blood, 2013, 122, 2925-2925.	1.4	0
41	Survival Disparities By Insurance Type For Patients With Non-Hodgkin Lymphoma. Blood, 2013, 122, 1737-1737.	1.4	0
42	Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008–2012. Cancer Epidemiology, 2012, 36, e19-e25.	1.9	19
43	Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointestinal Endoscopy, 2012, 75, 621-630.e1.	1.0	39
44	Erythropoietin Levels in Patients with Sickle Cell Disease Not in Vaso-Occlusive Crisis. Blood, 2012, 120, 3242-3242.	1.4	2
45	Red Cell Alloimmunization in Sickle Cell Disease: Benefit of Extended Crossmatching in Adults. Blood, 2012, 120, 4761-4761.	1.4	6
46	Population Level Survival of Patients with Chronic Myeloid Leukemia in Germany in the Early 21st Century. Blood, 2012, 120, 759-759.	1.4	0
47	CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 367-372.	0.4	63
48	Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data. Oncologist, 2011, 16, 1600-1603.	3.7	131
49	Survival of Patients with Chronic Myelocytic Leukemia: Comparisons of Estimates from Clinical Trial Settings and Population-Based Cancer Registries. Oncologist, 2011, 16, 663-671.	3.7	34
50	Population Level Survival for Patients with Multiple Myeloma: Variation and Growing Disparity for Patients of Minority Race or Ethnicity. Blood, 2011, 118, 3126-3126.	1.4	0
51	Changes in Survival in Acute Myeloblastic Leukemia by Racial and Ethnic Group: Greater Improvement for Non-Hispanic Whites and Increase in the Disparity for Minority Patients in the Early 21st Century. Blood, 2011, 118, 844-844.	1.4	0
52	Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. Oncologist, 2010, 15, 994-1001.	3.7	623
53	Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, $1981\hat{a} \in 2005$ . Cancer, 2009, 115, 4973-4979.	4.1	56
54	Long-term survival in chronic myelocytic leukemia after a first primary malignancy. Leukemia Research, 2009, 33, 1604-1608.	0.8	4

E DIANNE PULTE

#	Article	IF	CITATIONS
55	Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leukemia and Lymphoma, 2009, 50, 179-186.	1.3	16
56	Survival Expectations of Patients Diagnosed with Hodgkin's Lymphoma in 2006–2010. Oncologist, 2009, 14, 806-813.	3.7	19
57	Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood, 2009, 113, 1408-1411.	1.4	202
58	Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica, 2009, 94, 270-275.	3.5	113
59	Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990–2004. Journal of the National Cancer Institute, 2008, 100, 1301-1309.	6.3	107
60	Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century. Archives of Internal Medicine, 2008, 168, 469.	3.8	78
61	Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood, 2008, 111, 2521-2526.	1.4	495
62	Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood, 2008, 111, 2977-2983.	1.4	103
63	Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood, 2008, 111, 4916-4921.	1.4	133
64	Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica, 2008, 93, 594-600.	3.5	99
65	Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica, 2008, 93, 1544-1549.	3.5	39
66	Ongoing Strong Improvement in Treatment Outcomes for Patients Diagnosed with Non-Hodgkin Lymphoma from the 1990s to the Early 21st Century Blood, 2007, 110, 3314-3314.	1.4	0